miRagen Therapeutics, Inc., a biopharmaceutical company focused on
improving patients’ lives by developing innovative microRNA
(miRNA)-based therapeutics for cardiovascular and muscle disease,
announced today the formation of the company’s world renowned Scientific
Advisory Board (SAB). The SAB was established to provide miRagen with
valuable guidance in developing an extensive pipeline of microRNA-based
drugs and is comprised of leaders who are internationally recognized
experts in their respective fields. The SAB is lead by miRagen’s Chief
Scientific Advisor and Co-Founder, Eric N. Olson, Ph.D. The first
appointed members include Nobel Prize in Chemistry winner Thomas R.
Cech, Ph.D., Distinguished Professor at the University of
Colorado-Boulder, Investigator of the Howard Hughes Medical Institute
and Director of the Colorado Initiative in Molecular Biotechnology.
“To collaborate with this team of thought leaders is an honor”
“We are delighted to have assembled such a distinguished team to help
advise the company on its research and development pipeline,” said
William S. Marshall, Ph.D., President and Chief Executive Officer of
miRagen Therapeutics, Inc. “To have an SAB of this caliber intimately
involved in miRagen’s drug discovery programs will be vital not only to
the company’s success but also, and more importantly, to the millions of
patients suffering from cardiovascular and muscle disease.”
“The science underlying miRagen’s therapies is highly innovative and
represents a significant advancement in RNA research,” said Dr. Cech. “I
look forward to working closely with my esteemed colleagues and
miRagen’s team to translate breakthrough discoveries into therapies for
patients who suffer from these debilitating diseases.”
“To collaborate with this team of thought leaders is an honor,” added
Dr. Olson. “Each member brings unparalleled knowledge and experience to
the table. Together, I believe we have an opportunity to create some
truly unique RNA-based therapeutics. The SAB will be instrumental to the
success of miRagen’s research and development pipeline.”
The members of miRagen’s Scientific Advisory Board are: